KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Short-term Investments: 2013-2025

Historic Short-term Investments for Sarepta Therapeutics (SRPT) over the last 12 years, with Sep 2025 value amounting to $237.9 million.

  • Sarepta Therapeutics' Short-term Investments fell 76.22% to $237.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $237.9 million, marking a year-over-year decrease of 76.22%. This contributed to the annual value of $251.8 million for FY2024, which is 79.82% down from last year.
  • According to the latest figures from Q3 2025, Sarepta Therapeutics' Short-term Investments is $237.9 million, which was down 17.83% from $289.5 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Short-term Investments ranged from a high of $1.2 billion in Q4 2023 and a low of $30.0 million during Q2 2021.
  • Over the past 3 years, Sarepta Therapeutics' median Short-term Investments value was $1.0 billion (recorded in 2024), while the average stood at $778.2 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first slumped by 92.88% in 2021, then soared by 3,431.67% in 2022.
  • Sarepta Therapeutics' Short-term Investments (Quarterly) stood at $30.0 million in 2021, then soared by 3,431.67% to $1.0 billion in 2022, then grew by 22.02% to $1.2 billion in 2023, then slumped by 79.82% to $251.8 million in 2024, then tumbled by 76.22% to $237.9 million in 2025.
  • Its last three reported values are $237.9 million in Q3 2025, $289.5 million for Q2 2025, and $281.9 million during Q1 2025.